Hemorrhoids – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Hemorrhoids Market Outlook
Thelansis’s “Hemorrhoids Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Hemorrhoids treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Hemorrhoids Overview
Hemorrhoids,
or piles, result from enlarged or varicose veins in the anus and rectum.
Internal hemorrhoids develop above the dentate line and are typically painless
due to their visceral innervation. The precise cause of hemorrhoids remains
uncertain. Upright posture places significant pressure on rectal veins,
potentially leading to bulging. Other contributing factors encompass aging,
chronic constipation or diarrhea, pregnancy, heredity, straining during bowel
movements, faulty bowel function from overuse of laxatives or enemas, and
prolonged periods spent on the toilet, such as while reading. Hemorrhoids often
exhibit no symptoms or may protrude. Hemorrhoids are generally not responsible
for pruritus ani unless they are substantially prolapsed. External hemorrhoids
can become thrombosed, resulting in painful, purplish swelling and, rarely,
ulceration with minor bleeding, making anal cleansing challenging. Internal
hemorrhoids usually present with bleeding after defecation, where blood is
observed on toilet paper and occasionally in the toilet bowl. While internal
hemorrhoids can be uncomfortable, they are less painful than thrombosed
external hemorrhoids. Internal hemorrhoids may also lead to mucus discharge and
a sensation of incomplete evacuation. Strangulated hemorrhoids occur when the
protrusion and constriction block the blood supply, causing pain, potential
necrosis, and ulceration. Hemorrhoids are categorized based on their
presentation: grade I involves hemorrhoids that do not prolapse and appear as bulges
in the anal canal with or without bleeding. Grade II hemorrhoids prolapse but
reduce spontaneously. Grade III hemorrhoids require digital reduction of
prolapsed tissue. Grade IV hemorrhoidal piles are irreducible. Complications of
hemorrhoids may include – Blood clots in an external hemorrhoid, Skin tags are
extra skin left behind when a blood clot in an external hemorrhoid dissolves,
Infection of a sore on an external hemorrhoid, Strangulated hemorrhoid, where
the muscles around the anus cut off blood supply to an internal hemorrhoid that
has fallen through the anal opening. The primary conservative treatment for
hemorrhoids includes a high-fiber diet (25 to 35 grams daily), fiber
supplements, increased water intake, warm water sitz baths, and stool
softeners. Prescription therapies may also be used as part of the initial
treatment, with topical nitroglycerin effectively reducing rectal pain caused
by thrombosed hemorrhoids. However, it is more commonly used for anal fissures.
Office-based and surgical procedures can be effective for hemorrhoids that do
not respond to medical therapies. Generally, the lower the grade of
hemorrhoids, the more successful an office-based procedure is likely to be
while recurring, and grade III or IV hemorrhoids are more amenable to
excisional hemorrhoidectomy. In the United States, hemorrhoid disease ranks as
the fourth leading outpatient gastrointestinal diagnosis, accounting for 3.3
million ambulatory care visits.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment